Localized- and advanced-stage follicular lymphomas differ in their gene expression profiles | Blood | American Society of Hematology
You do not currently have access to this content.
Related Articles
Unbalanced MYC break-apart FISH patterns indicate the presence of a MYC rearrangement in HGBCL-DH-BCL2
Key PointsUnbalanced MYC break-apart FISH patterns, in which red or green signal is lost, are observed in ∼13% of HGBCL-DH-BCL2 tumors.Balanced and unbalan
Real-world treatment patterns and outcomes in relapsed/refractory multiple myeloma (1-3 prior lines): Flatiron database
Key PointsReal-world patients with lenalidomide-refractory MM and 1 to 3 prior LOT progress rapidly through therapies.Outcomes remain suboptimal, despite g
Use of HSC-targeted LNP to generate a mouse model of lethal α-thalassemia and treatment via lentiviral gene therapy
Key PointsDeletion of the α-globin genes induces a lethal phenotype associated with high levels of red blood cells in circulation.Transduction with a lenti
Differential inflammatory conditioning of the bone marrow by acute myeloid leukemia and its impact on progression
Key PointsAn inflammatory BMM with elevated levels of PGE2 accelerates the progression of PGE2-sensitive AML.A specific subset of patients with AML may ben
Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma
Key Points. Cumulative fracture incidence after R-CHOP in older patients (>70 years) is high (11.4% at 18 months).Bone involvement, prephase steroids, or eit
Genetic medicine gestating for α-thalassemia
In this issue of Blood, Chappell et al describe a pair of innovations, a novel mouse model and an effective gene therapy approach, that renew prospects…
Unexpected diagnosis of WHIM syndrome in refractory autoimmune cytopenia
Key PointsA rare mutation in CXCR4 led to life-long autoimmunity and lymphoid hypertrophy in several members of a kindred.Lack of characteristic features o
Optimizing drug combinations for T-PLL: restoring DNA damage and P53-mediated apoptotic responses
Key PointsThe inability of T-PLL cells to evoke adequate P53 responses makes them vulnerable to inhibitors of (H)DAC, BCL2, CDK, and MDM2.Pharmacologic gen
Health-related quality of life with gilteritinib vs placebo posttransplant for FLT3-ITD+ acute myeloid leukemia
Key PointsGilteritinib maintenance therapy after allogeneic HCT in FLT3-ITD AML is not associated with any difference in HRQOL compared with placebo.Despit
A T-ALL order: a new risk classifier for T-ALL
In this issue of Blood, Simonin et al propose a next-generation sequencing (NGS)-based risk classifier for patients with T-cell acute lymphoblastic leukemi
